Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR
laurabbook@gmail.com2019-03-17T11:39:10-07:00*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of
17
March 2019
17
March 2019
Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance
laurabbook@gmail.com2019-03-17T11:10:16-07:00*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the
14
March 2019
Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon
laurabbook@gmail.com2019-03-14T10:04:41-07:00*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for
3
February 2019
Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients
laurabbook@gmail.com2019-02-11T13:17:42-07:00*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung
3
February 2019
A cancer researcher reflects on the evolution of lung cancer therapies
laurabbook@gmail.com2019-02-03T11:20:23-07:00*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to
3
February 2019
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC
laurabbook@gmail.com2019-02-03T11:06:16-07:00*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had
5
January 2019
OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?
laurabbook@gmail.com2019-01-05T11:08:03-07:00*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.
4
January 2019
Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer
laurabbook@gmail.com2019-01-05T11:18:38-07:00*December 10, 2018, University of Texas M. D. Anderson Cancer Center* Researchers at The University of Texas MD Anderson Cancer Center
4
January 2019
Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer
laurabbook@gmail.com2019-01-04T18:45:14-07:00June 12 2018. A first of its kind treatment vaccine has moved into a phase I clinical trial for patients
22
November 2018
PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS
laurabbook@gmail.com2018-11-22T13:19:38-07:00Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer